These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 32702304)

  • 1. Continuous surveillance of invasive pneumococcal disease is key.
    Knol MJ; van der Ende A
    Lancet Infect Dis; 2021 Jan; 21(1):13-14. PubMed ID: 32702304
    [No Abstract]   [Full Text] [Related]  

  • 2. Underlying factors in paediatric invasive pneumococcal disease in Belgium.
    Izurieta P; Scherbakov M; Vetter V
    Lancet Infect Dis; 2021 Feb; 21(2):169-170. PubMed ID: 33515517
    [No Abstract]   [Full Text] [Related]  

  • 3. Underlying factors in paediatric invasive pneumococcal disease in Belgium - Authors' reply.
    Desmet S; Lagrou K; Peetermans WE; Blumental S
    Lancet Infect Dis; 2021 Feb; 21(2):170. PubMed ID: 33515519
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of pneumococcal conjugate vaccines on invasive pneumococcal disease.
    Camargos P; Drumond E; Nascimento-Carvalho CM
    Lancet Infect Dis; 2021 Apr; 21(4):453. PubMed ID: 33773123
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of pneumococcal conjugate vaccines on invasive pneumococcal disease - Authors' reply.
    de Cunto Brandileone MC; Castañeda-Orjuela C; Almeida SCG; Andrade AL
    Lancet Infect Dis; 2021 Apr; 21(4):453-454. PubMed ID: 33773124
    [No Abstract]   [Full Text] [Related]  

  • 6. Impact of conjugate 7-valent vaccination in Belgium: addressing methodological challenges.
    Hanquet G; Lernout T; Vergison A; Verhaegen J; Kissling E; Tuerlinckx D; Malfroot A; Swennen B; Sabbe M;
    Vaccine; 2011 Apr; 29(16):2856-64. PubMed ID: 21342667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Issues in pneumococcal disease and pneumococcal conjugate vaccines: highlights of the 27th meeting of ESPID, Brussels, Belgium, June 9-13, 2009.
    Adam D
    Vaccine; 2009 Nov; 27(50):7133-7. PubMed ID: 19883868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The conjugate vaccine and invasive pneumococcal disease.
    Fedson DS
    N Engl J Med; 2003 Aug; 349(7):714-6; author reply 714-6. PubMed ID: 12917316
    [No Abstract]   [Full Text] [Related]  

  • 9. [Incidence of invasive pneumococcal infection in children aged less than two years. The heptavalent pneumococcal conjugate vaccine. Situation in Spain].
    Blanco Quirós A; Giménez Sánchez F; Asensi Botet F; Bernaola Iturbe E; Martín Fde J; García Pérez J; Garcés Sánchez M; Gómez Campderá JA; Picazo JJ; Pineda Solas V;
    An Esp Pediatr; 2002 Oct; 57(4):287-9. PubMed ID: 12392660
    [No Abstract]   [Full Text] [Related]  

  • 10. Prediction of the potential benefit of different pneumococcal conjugate vaccines on invasive pneumococcal disease in German children.
    von Kries R; Hermann M; Hachmeister A; Siedler A; Schmitt HJ; Al-Lahham A; Reinert RR
    Pediatr Infect Dis J; 2002 Nov; 21(11):1017-23. PubMed ID: 12442022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges in estimating the impact of pneumococcal conjugate vaccines through surveillance.
    Vergison A; Hanquet G
    Pediatr Infect Dis J; 2012 Apr; 31(4):400-3. PubMed ID: 22418653
    [No Abstract]   [Full Text] [Related]  

  • 12. 27th Annual Meeting of the European Society for Pediatric Infectious Disease.
    Dinleyici EC; Yargic ZA
    Expert Rev Vaccines; 2009 Sep; 8(9):1143-9. PubMed ID: 19722887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct effects of pneumococcal conjugate vaccines among children in Latin America and the Caribbean.
    Whitney CG; Toscano CM
    Lancet Infect Dis; 2021 Mar; 21(3):306-308. PubMed ID: 32986995
    [No Abstract]   [Full Text] [Related]  

  • 14. Understanding the link between pneumococcal serotypes and invasive disease.
    Soley C; Arguedas A
    Vaccine; 2009 Aug; 27 Suppl 3():C19-21. PubMed ID: 19535183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Introduction of the 13-valent pneumococcal conjugate vaccine in an isolated pneumococcal vaccine-naïve indigenous population.
    Verhagen LM; Rivera-Olivero IA; Hermsen M; Sisco MC; Maes M; Del Nogal B; Bogaert D; Berbers GA; Hermans PW; de Jonge MI; de Waard JH
    Eur Respir J; 2016 Nov; 48(5):1492-1496. PubMed ID: 27540017
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections.
    Zangeneh TT; Baracco G; Al-Tawfiq JA
    Expert Rev Vaccines; 2011 Mar; 10(3):345-53. PubMed ID: 21434802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente.
    Black S; Shinefield H; Baxter R; Austrian R; Bracken L; Hansen J; Lewis E; Fireman B
    Pediatr Infect Dis J; 2004 Jun; 23(6):485-9. PubMed ID: 15194827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of invasive pneumococcal disease in children 3 to 36 months of age at a tertiary care pediatric center 2 years after licensure of the pneumococcal conjugate vaccine.
    Lin PL; Michaels MG; Janosky J; Ortenzo M; Wald ER; Mason EO
    Pediatrics; 2003 Apr; 111(4 Pt 1):896-9. PubMed ID: 12671130
    [No Abstract]   [Full Text] [Related]  

  • 19. The conjugate vaccine and invasive pneumococcal disease.
    Konradsen HB; Nokleby H
    N Engl J Med; 2003 Aug; 349(7):714-6; author reply 714-6. PubMed ID: 12921091
    [No Abstract]   [Full Text] [Related]  

  • 20. Antibiotic resistance and the potential impact of pneumococcal conjugate vaccines.
    Dagan R
    Commun Dis Intell Q Rep; 2003; 27 Suppl():S134-42. PubMed ID: 12807290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.